NASDAQ · MDGL
Madrigal Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MDGL: Nov 03, 2026
Madrigal Pharmaceuticals, Inc. Common Stock is expected to report earnings on 11/03/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.09. The reported EPS for the same quarter last year was $-5.08.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.09 | $-0.10 | $-2.00 | 6 |
| Dec 2026 | $-0.57 | $0.85 | $-1.51 | 5 |
| Mar 2027 | $-1.83 | $-1.83 | $-1.83 | 1 |
| Jun 2027 | $0.72 | $0.72 | $0.72 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · The Motley Fool · MarketBeat- Zacks · Oct 28, 9:00 AM EDTAnalysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out forUnited Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 27, 9:00 AM EDTWill Madrigal (MDGL) Report Negative Earnings Next Week? What You Should KnowMadrigal (MDGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 7, 9:02 AM EDTCan NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and clinical risks loom.
- The Motley Fool · Sep 10, 12:20 PM EDTInstitutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?Madrigal's only commercial drug, Rezdiffra, continues to grow sales.
- The Motley Fool · Aug 25, 12:20 PM EDTHere's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take OffMASH cirrhosis could significantly expand Rezdiffra’s addressable market.
- Zacks · Aug 19, 10:55 AM EDTIs Altimmune Worth Buying as Cash Rises but Execution Risks Linger?ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.
- MarketBeat · Aug 15, 5:01 AM EDTMadrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline ExpandsMarketBeat Week in Review – 09/08 – 09/12Madrigal Pharmaceuticals (NASDAQ:MDGL) said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH therapy and prepared for several potential
- Zacks · Jul 31, 11:34 AM EDTMDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y GrowthMadrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as investors weigh slower commercial growth.
- MarketBeat · Jul 30, 2:04 PM EDTMadrigal Pharmaceuticals Q2 Earnings Call HighlightsMarketBeat Week in Review – 09/08 – 09/12Madrigal Pharmaceuticals (NASDAQ:MDGL) reported second-quarter 2026 net sales of $364.3 million for Rezdiffra, up 71% from a year earlier, as the company continued to expand the number of patients receiving its treatment for metabolic dysf
- Zacks · Jul 30, 8:35 AM EDTMadrigal (MDGL) Reports Q2 Loss, Beats Revenue EstimatesMadrigal (MDGL) delivered earnings and revenue surprises of +21.96% and +4.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 29, 6:25 PM EDTCorcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass EstimatesCorcept (CORT) delivered earnings and revenue surprises of +1,000.00% and +18.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- The Motley Fool · Jul 10, 2:50 PM EDT3 Under-the-Radar Stocks to Buy and HoldThese three biotechs are posting strong revenue growth.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Madrigal Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.